Medtech’s subscription surge: giants double down on recurring revenue as diabetes tech arms race heats up

Intuitive Surgical has adeptly transitioned from a capital equipment vendor to a procedure-driven recurring revenue powerhouse, with 84% of its $10.06 billion fiscal 2025 revenue stemming from instruments, service contracts, and leases. This razor-blades model, where disposable instruments and accessories scale directly with clinical usage, was highlighted by a 23% increase in instruments revenue in Q1 2026, outpacing system sales and underscoring the durability of its ecosystem.

The growth of Intuitive’s installed base and procedure volumes is central to its recurring revenue expansion, with the da Vinci system base rising from 9,902 units in 2024 to 11,106 by the end of 2025, and global procedures surging 18% to over 3.15 million. This steady procedural momentum, coupled with innovations like the AI-integrated Da Vinci 5 rollout, reinforces the company’s strategy to deepen utilization rather than merely increasing system placements.

Medtronic exemplifies the legacy medtech giant evolving into a diversified platform, leveraging a broad installed base across Cardiovascular, Neuroscience, Medical Surgical, and Diabetes segments to generate recurring revenue through upgrades and service contracts. Its fiscal 2025 results—$33.54 billion in net sales and $2.7 billion invested in R&D—reflect a scale innovator balancing growth and innovation, with Q3 2026 sales rising across all major segments, illustrating resilience through portfolio diversification.

ViCentra has rapidly scaled its Kaleido insulin patch pump system, tripling production capacity to serve over 17,000 users and targeting key European markets such as Germany, the Netherlands, and France. This expansion is underpinned by integration of Diabeloop’s hybrid closed-loop algorithm, which enhances patient comfort and diabetes management through advanced automation. Looking ahead, ViCentra aims to disrupt the U.S. market with the 2027 launch of Kaleido 2, promising improved size, functionality, and smartphone control to challenge established competitors.

Insulet has transformed from a single-device maker into a robust tubeless-pump platform driven by a recurring revenue model centered on disposable Pods replaced every three days. By early 2026, Omnipod revenue surged 36.9% in Q1 to $758.4 million, supported by a growing global installed base exceeding 600,000 users and aggressive geographic expansion, including launches in nine new markets in 2025 and five Middle Eastern countries in early 2026. This platform approach leverages pharmacy channels in the U.S. to lower upfront costs, fueling adoption and recurring consumable sales that now represent a significant portion of revenue.

Insulet’s platform maturation is reflected in its financial performance and technological integration efforts. Despite some margin pressure from inventory and warranty costs related to a voluntary device correction, the company posted a strong operating income of $122.1 million in Q1 2026, with full-year 2025 operating income at $473.8 million and gross margins stabilizing around 71%. Concurrently, Insulet is deepening its ecosystem by incorporating advanced algorithms and sensor technologies through partnerships with Abbott, Dexcom, and Glooko, exemplified by the Omnipod 5 algorithm update and limited U.S. release pairing with Abbott’s FreeStyle Libre 3 Plus sensor, embedding the platform more fully into diabetes management workflows.

By mid-2026, Zuuka emerged as a pioneering startup aiming to revolutionize wearable insulin delivery through its miniaturized pump platform that promises to slash medical waste by up to 99% compared to traditional disposable systems. This innovation hinges on a low-power, reusable pump body paired with replaceable infusion components, signaling a significant leap toward sustainability in medtech. Currently, Zuuka is in the midst of raising $1.5–$2 million to advance prototype development, conduct user trials, integrate smartphone and cloud-based tools, and navigate regulatory pathways, with an initial approval targeted in New Zealand and a planned U.S. launch by 2029.

Zuuka’s platform is designed not only to minimize environmental impact but also to enhance patient adherence by integrating continuous glucose monitoring, smartphone applications, and cloud-based clinician tools. This holistic approach addresses persistent barriers such as treatment complexity and stigma, aiming to reduce the burden on patients managing diabetes daily. By embedding connectivity and data-driven support, Zuuka exemplifies the next frontier in medtech innovation where sustainability and user-centric design converge to improve long-term health outcomes.